399 related articles for article (PubMed ID: 19527763)
21. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
[TBL] [Abstract][Full Text] [Related]
22. Correlation of attention deficit, rapid eye movement latency and slow wave sleep in schizophrenia patients.
Chang YS; Hsu CY; Tang SH; Lin CY; Chen MC
Psychiatry Clin Neurosci; 2009 Apr; 63(2):176-9. PubMed ID: 19335387
[TBL] [Abstract][Full Text] [Related]
23. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
[TBL] [Abstract][Full Text] [Related]
24. Blunted inhibition of return in schizophrenia-evidence from a longitudinal study.
Gouzoulis-Mayfrank E; Heekeren K; Voss T; Moerth D; Thelen B; Meincke U
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):389-96. PubMed ID: 14751438
[TBL] [Abstract][Full Text] [Related]
25. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ
J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428
[TBL] [Abstract][Full Text] [Related]
26. Positive and negative spatial priming in schizophrenia.
Zimmermann M; Stark R; Kern G; Laiacker M; Kirsch P; Vaitl D
J Clin Exp Neuropsychol; 2006 Jul; 28(5):706-20. PubMed ID: 16723319
[TBL] [Abstract][Full Text] [Related]
27. Deficit of endogenous spatial orienting of attention in children with benign epilepsy with centrotemporal spikes (BECTS).
Deltour L; Querné L; Vernier-Hauvette MP; Berquin P
Epilepsy Res; 2008 May; 79(2-3):112-9. PubMed ID: 18329247
[TBL] [Abstract][Full Text] [Related]
28. Attentional disengagement dysfunction following mTBI assessed with the gap saccade task.
Drew AS; Langan J; Halterman C; Osternig LR; Chou LS; van Donkelaar P
Neurosci Lett; 2007 Apr; 417(1):61-5. PubMed ID: 17363165
[TBL] [Abstract][Full Text] [Related]
29. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
30. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
[TBL] [Abstract][Full Text] [Related]
31. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
32. Attention to gaze and emotion in schizophrenia.
Schwartz BL; Vaidya CJ; Howard JH; Deutsch SI
Neuropsychology; 2010 Nov; 24(6):711-20. PubMed ID: 20873932
[TBL] [Abstract][Full Text] [Related]
33. Deficient inhibition of return in schizophrenia-further evidence from an independent sample.
Gouzoulis-Mayfrank E; Arnold S; Heekeren K
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):42-9. PubMed ID: 16014319
[TBL] [Abstract][Full Text] [Related]
34. [Saccadic reaction times and visuospatial disorders of attention in schizophrenic patients with negative symptoms].
Mackert A; Flechtner M; Frick K
Fortschr Neurol Psychiatr; 1989 Dec; 57(12):535-43. PubMed ID: 2613156
[TBL] [Abstract][Full Text] [Related]
35. Attentional mechanisms of saccadic eye movements in schizophrenia.
Evans WJ; Schwartz BD
Neuropsychiatry Neuropsychol Behav Neurol; 1997 Jan; 10(1):17-24. PubMed ID: 9118193
[TBL] [Abstract][Full Text] [Related]
36. Attention network test (ANT) reveals gender-specific alterations of executive function in schizophrenia.
Urbanek C; Neuhaus AH; Opgen-Rhein C; Strathmann S; Wieseke N; Schaub R; Hahn E; Dettling M
Psychiatry Res; 2009 Jul; 168(2):102-9. PubMed ID: 19464736
[TBL] [Abstract][Full Text] [Related]
37. Disentangling the attentional deficit in schizophrenia: pointers from schizotypy.
Le Pelley ME; Schmidt-Hansen M; Harris NJ; Lunter CM; Morris CS
Psychiatry Res; 2010 Apr; 176(2-3):143-9. PubMed ID: 20138371
[TBL] [Abstract][Full Text] [Related]
38. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
Levine SZ; Rabinowitz J
J Clin Psychopharmacol; 2007 Oct; 27(5):431-6. PubMed ID: 17873671
[TBL] [Abstract][Full Text] [Related]
39. Controlling the spotlight of attention: visual span size and flexibility in schizophrenia.
Elahipanah A; Christensen BK; Reingold EM
Neuropsychologia; 2011 Oct; 49(12):3370-6. PubMed ID: 21871907
[TBL] [Abstract][Full Text] [Related]
40. Sustained attention in the context of emotional processing in patients with schizophrenia.
Park SH; Kim JJ; Kim CH; Kim JH; Lee KH
Psychiatry Res; 2011 May; 187(1-2):18-23. PubMed ID: 21115200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
